Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more
Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Net Assets
Latest net assets as of September 2025: CN¥5.69 Billion CNY
Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has net assets worth CN¥5.69 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.98 Billion) and total liabilities (CN¥2.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.69 Billion |
| % of Total Assets | 71.26% |
| Annual Growth Rate | 24.25% |
| 5-Year Change | 52.61% |
| 10-Year Change | 165.5% |
| Growth Volatility | 52.77 |
Zhejiang Jingxin Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)
This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual net assets of Zhejiang Jingxin Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.00 Billion | +8.33% |
| 2023-12-31 | CN¥5.54 Billion | +7.12% |
| 2022-12-31 | CN¥5.17 Billion | +6.91% |
| 2021-12-31 | CN¥4.84 Billion | +23.01% |
| 2020-12-31 | CN¥3.93 Billion | +5.98% |
| 2019-12-31 | CN¥3.71 Billion | +3.84% |
| 2018-12-31 | CN¥3.57 Billion | -9.89% |
| 2017-12-31 | CN¥3.97 Billion | +63.43% |
| 2016-12-31 | CN¥2.43 Billion | +7.34% |
| 2015-12-31 | CN¥2.26 Billion | +61.63% |
| 2014-12-31 | CN¥1.40 Billion | +70.98% |
| 2013-12-31 | CN¥817.98 Million | +5.88% |
| 2012-12-31 | CN¥772.58 Million | +0.84% |
| 2011-12-31 | CN¥766.17 Million | +139.33% |
| 2010-12-31 | CN¥320.13 Million | +4.22% |
| 2009-12-31 | CN¥307.17 Million | +1.31% |
| 2008-12-31 | CN¥303.19 Million | +1.20% |
| 2007-12-31 | CN¥299.61 Million | +1.70% |
| 2006-12-31 | CN¥294.62 Million | +1.72% |
| 2005-12-31 | CN¥289.64 Million | +1.98% |
| 2004-12-31 | CN¥284.03 Million | +221.15% |
| 2003-12-31 | CN¥88.44 Million | +40.34% |
| 2002-12-31 | CN¥63.02 Million | +54.95% |
| 2001-12-31 | CN¥40.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Jingxin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 121558.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.90 Billion | 48.54% |
| Common Stock | CN¥861.03 Million | 14.42% |
| Other Comprehensive Income | CN¥487.65 Million | 8.17% |
| Other Components | CN¥1.72 Billion | 28.87% |
| Total Equity | CN¥5.97 Billion | 100.00% |
Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maze Therapeutics, Inc. Common Stock
NASDAQ:MAZE
|
$934.69 Million |
|
New World Development Company Limited
PINK:NWWDF
|
$934.90 Million |
|
Bringspring Science and Tech
SHE:300290
|
$934.91 Million |
|
Insperity Inc
NYSE:NSP
|
$935.40 Million |
|
BNP Paribas Bank Polska S.A.
WAR:BNP
|
$934.52 Million |
|
Lifestyle Communities Limited
PINK:LCOMF
|
$933.84 Million |
|
Community Trust Bancorp Inc
NASDAQ:CTBI
|
$933.83 Million |
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
$933.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Jingxin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,512,374,486 to 5,969,508,653, a change of 457,134,167 (8.3%).
- Net income of 711,961,466 contributed positively to equity growth.
- Dividend payments of 258,308,742 reduced retained earnings.
- Other comprehensive income increased equity by 99,675,438.
- Other factors decreased equity by 96,193,995.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥711.96 Million | +11.93% |
| Dividends Paid | CN¥258.31 Million | -4.33% |
| Other Comprehensive Income | CN¥99.68 Million | +1.67% |
| Other Changes | CN¥-96.19 Million | -1.61% |
| Total Change | CN¥- | 8.29% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Jingxin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 327.20x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.04 | CN¥14.70 | x |
| 2002-12-31 | CN¥0.07 | CN¥14.70 | x |
| 2003-12-31 | CN¥0.17 | CN¥14.70 | x |
| 2004-12-31 | CN¥0.58 | CN¥14.70 | x |
| 2005-12-31 | CN¥0.59 | CN¥14.70 | x |
| 2006-12-31 | CN¥0.60 | CN¥14.70 | x |
| 2007-12-31 | CN¥0.62 | CN¥14.70 | x |
| 2008-12-31 | CN¥0.62 | CN¥14.70 | x |
| 2009-12-31 | CN¥0.62 | CN¥14.70 | x |
| 2010-12-31 | CN¥0.65 | CN¥14.70 | x |
| 2011-12-31 | CN¥1.51 | CN¥14.70 | x |
| 2012-12-31 | CN¥1.27 | CN¥14.70 | x |
| 2013-12-31 | CN¥1.35 | CN¥14.70 | x |
| 2014-12-31 | CN¥2.16 | CN¥14.70 | x |
| 2015-12-31 | CN¥3.23 | CN¥14.70 | x |
| 2016-12-31 | CN¥3.11 | CN¥14.70 | x |
| 2017-12-31 | CN¥4.87 | CN¥14.70 | x |
| 2018-12-31 | CN¥4.11 | CN¥14.70 | x |
| 2019-12-31 | CN¥4.54 | CN¥14.70 | x |
| 2020-12-31 | CN¥4.95 | CN¥14.70 | x |
| 2021-12-31 | CN¥5.90 | CN¥14.70 | x |
| 2022-12-31 | CN¥5.98 | CN¥14.70 | x |
| 2023-12-31 | CN¥6.41 | CN¥14.70 | x |
| 2024-12-31 | CN¥6.96 | CN¥14.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Jingxin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.93%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.12%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.42x
- Recent ROE (11.93%) is above the historical average (10.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 24.52% | 4.39% | 1.49x | 3.75x | CN¥5.91 Million |
| 2002 | 35.36% | 8.25% | 1.48x | 2.89x | CN¥15.98 Million |
| 2003 | 28.72% | 8.43% | 1.16x | 2.93x | CN¥16.56 Million |
| 2004 | 9.23% | 7.41% | 0.75x | 1.66x | CN¥-2.16 Million |
| 2005 | 6.53% | 6.11% | 0.53x | 2.01x | CN¥-9.81 Million |
| 2006 | 4.79% | 3.24% | 0.56x | 2.64x | CN¥-15.28 Million |
| 2007 | 0.50% | 0.27% | 0.56x | 3.41x | CN¥-28.31 Million |
| 2008 | -5.92% | -3.47% | 0.54x | 3.18x | CN¥-47.66 Million |
| 2009 | 1.24% | 0.71% | 0.58x | 3.03x | CN¥-26.55 Million |
| 2010 | 4.08% | 2.04% | 0.66x | 3.00x | CN¥-18.70 Million |
| 2011 | 3.80% | 4.10% | 0.60x | 1.56x | CN¥-47.50 Million |
| 2012 | 4.10% | 3.69% | 0.66x | 1.68x | CN¥-45.58 Million |
| 2013 | 7.87% | 6.60% | 0.74x | 1.62x | CN¥-17.45 Million |
| 2014 | 7.66% | 8.67% | 0.60x | 1.48x | CN¥-32.77 Million |
| 2015 | 7.49% | 11.73% | 0.48x | 1.33x | CN¥-55.64 Million |
| 2016 | 8.39% | 10.65% | 0.57x | 1.38x | CN¥-38.35 Million |
| 2017 | 6.74% | 11.91% | 0.45x | 1.25x | CN¥-127.68 Million |
| 2018 | 10.37% | 12.54% | 0.59x | 1.40x | CN¥13.10 Million |
| 2019 | 14.08% | 14.27% | 0.65x | 1.52x | CN¥150.79 Million |
| 2020 | 16.67% | 20.04% | 0.57x | 1.45x | CN¥261.31 Million |
| 2021 | 12.72% | 17.67% | 0.54x | 1.33x | CN¥130.80 Million |
| 2022 | 12.87% | 17.52% | 0.51x | 1.43x | CN¥147.64 Million |
| 2023 | 11.23% | 15.48% | 0.50x | 1.45x | CN¥67.66 Million |
| 2024 | 11.93% | 17.12% | 0.49x | 1.42x | CN¥115.01 Million |
Industry Comparison
This section compares Zhejiang Jingxin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,860,251,608
- Average return on equity (ROE) among peers: 9.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Jingxin Pharmaceutical Co Ltd (002020) | CN¥5.69 Billion | 24.52% | 0.40x | $934.55 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $868.76 Million | 4.89% | 3.05x | $585.75 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $303.51 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $3.24 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.83 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $5.56 Billion | 21.80% | 0.64x | $5.45 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $314.20 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.76 Billion | 3.15% | 2.10x | $393.66 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $720.42 Million | 13.93% | 0.65x | $1.92 Billion |
| Renhe Pharmacy Co Ltd (000650) | $4.35 Billion | 12.36% | 0.15x | $734.11 Million |
| Changchun High & New Technology Industries Group Inc (000661) | $416.50 Million | 1.72% | 2.35x | $3.31 Billion |